BCOR is altered in 5.26% of myelodysplastic syndromes patients [3].

BCOR is an inclusion criterion in 3 clinical trials for myelodysplastic syndromes, of which 3 are open and 0 are closed. Of the trials that contain BCOR status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

BCOR is altered in 6.18% of acute myeloid leukemia patients [3].

BCOR is an inclusion criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain BCOR status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

BCOR is altered in 3.61% of secondary acute myeloid leukemia patients [3].

BCOR is an inclusion criterion in 2 clinical trials for secondary acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain BCOR status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

BCOR is altered in 14.29% of acute lymphoblastic leukemia patients [3].

BCOR is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCOR status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

BCOR is altered in 3.61% of therapy-related acute myeloid leukemia patients [3].

BCOR is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCOR status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

BCOR is altered in 3.74% of chronic myelomonocytic leukemia patients [3].

BCOR is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCOR status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

BCOR is altered in 3.17% of myelodysplastic/myeloproliferative neoplasm patients [3].

BCOR is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BCOR status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BCOR is altered in 2.82% of therapy-related myelodysplastic syndrome patients [3].

BCOR is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains BCOR status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

BCOR is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains BCOR status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

BCOR is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains BCOR status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].